What They Are Saying: Voices Against Harmful Drug Pricing Policies

While some in Washington are proposing damaging drug pricing policies, including “Most Favored Nation,” China is gaining ground in clinical trials, drug approvals and breakthroughs. The unintended consequences of harmful drug pricing policies are substantial: stifled innovation in the biopharmaceutical sector; reduced access to life-saving treatments; and significant U.S. job losses across an industry that has long anchored American economic competitiveness.

This policy debate comes at a particularly strategic moment. As China and other nations aggressively expand their biotechnology investments, America faces a choice: maintain its innovative advantage or adopt harmful policies that could cede this critical ground to international competitors.

We Work For Health and other leading voices, including patient advocacy organizations, think tanks and healthcare groups, are raising serious concerns about the impact of the Most Favored Nation pricing proposals on innovation and jobs across America. Read what they are saying.